sean007 -- remember last year when you were jokingly messing with me for saying, LL could be the futuristic drug for space affects on the body??
Also 3-d printed housing units for the moon was already in planning. Welp, now with TONS more MOA/Kinetics known ---- i'll toss it out again for another laugh
Yur welcomed!! Hahaa
If any drug is showing a potential to address future space & duration affect --- it's our Leronlimab.
Yes, CCR5 (C-C chemokine receptor type 5) is affected by the conditions of space travel, primarily through the broad, stress-induced changes to the immune system caused by microgravity and space radiation.
While not often cited as the primary gene affected, it is part of the broader, complex immune system alterations that lead to weakened immune competence in astronauts.
PubMed Central (PMC) (.gov)
Key findings regarding CCR5 and spaceflight include:
Immune System Modulation:
Spaceflight causes a decrease in immunity and triggers dormant viruses (like Epstein-Barr and Herpes) to reactivate.
Studies on astronaut immune cells have shown that T regulatory cells (Tregs) become hyper-active, suppressing necessary immune responses in microgravity, a process that involves immune regulation pathways.
Genetic Expression Changes:
Long-duration space missions cause profound changes in gene expression in white blood cells, weakening the immune system.
Target for Countermeasures:
Because of its role in regulating the immune system and its influence on immune cell infiltration, research on CCR5 is often linked to efforts to mitigate inflammatory storms and other immune-related conditions. Some studies suggest that gene editing, such as targeting CCR5, could potentially enhance immune resilience against the harsh environment of deep space, though this is theoretical, controversial, and in early research stages.
University of California
In summary, the reduced effectiveness of the immune system in space, which includes changes to CCR5-mediated processes and other immune regulatory mechanisms, is a major area of research for future long-duration missions.
PubMed Central (PMC) (.gov)
Like DOD, NASA too gets every breakthrough.
Leronlimab just might go to the moon....
Long Acting Leronlimab perhaps ?? : )
HA !
Also 3-d printed housing units for the moon was already in planning. Welp, now with TONS more MOA/Kinetics known ---- i'll toss it out again for another laugh
Yur welcomed!! Hahaa
If any drug is showing a potential to address future space & duration affect --- it's our Leronlimab.
Yes, CCR5 (C-C chemokine receptor type 5) is affected by the conditions of space travel, primarily through the broad, stress-induced changes to the immune system caused by microgravity and space radiation.
While not often cited as the primary gene affected, it is part of the broader, complex immune system alterations that lead to weakened immune competence in astronauts.
PubMed Central (PMC) (.gov)
Key findings regarding CCR5 and spaceflight include:
Immune System Modulation:
Spaceflight causes a decrease in immunity and triggers dormant viruses (like Epstein-Barr and Herpes) to reactivate.
Studies on astronaut immune cells have shown that T regulatory cells (Tregs) become hyper-active, suppressing necessary immune responses in microgravity, a process that involves immune regulation pathways.
Genetic Expression Changes:
Long-duration space missions cause profound changes in gene expression in white blood cells, weakening the immune system.
Target for Countermeasures:
Because of its role in regulating the immune system and its influence on immune cell infiltration, research on CCR5 is often linked to efforts to mitigate inflammatory storms and other immune-related conditions. Some studies suggest that gene editing, such as targeting CCR5, could potentially enhance immune resilience against the harsh environment of deep space, though this is theoretical, controversial, and in early research stages.
University of California
In summary, the reduced effectiveness of the immune system in space, which includes changes to CCR5-mediated processes and other immune regulatory mechanisms, is a major area of research for future long-duration missions.
PubMed Central (PMC) (.gov)
Like DOD, NASA too gets every breakthrough.
Leronlimab just might go to the moon....
Long Acting Leronlimab perhaps ?? : )
HA !
3